Omission of Local Therapies in Women Patients With HER2-positive or Triple-negative Breast Cancer

HER2-positive and Triple-negative are subtypes of breast cancer more sensitive to systemic therapies, where the complete pathological response rate may be higher than 50%. This gave rise to doubts about the usefulness of traditional local treatments for such responders. Omission of surgery after vacuum assisted breast biopsy (VABB) as well omission of radiotherapy after conservative surgery would now seem to be reasonable alternatives to standard care for highly selected patients, in whom systemic treatments have provided the maximum response.

Trial Details

NCT ID
NCT06938724
Phase
PHASE2
Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • Omission of local therapies
Locations (sample)
  • Milan, Italy|42.78235,12.59836

Key Eligibility Criteria

  • Women ≥ 18y.
  • Initial diagnosis of unifocal HER2-positive (regardless of HR status) or Triple-negative (HR positivity lower than 10% is allowed) T1-2, N0-1, M0 b…
  • Treated with neoadjuvant systemic treatment according to the center recommendations.
  • Maximum responders and/or complete pathological response proved by surgery.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →